Provided by Tiger Trade Technology Pte. Ltd.

Nuvectis Pharma, Inc.

21.12
+0.99004.92%
Post-market: 21.120.00000.00%16:10 EDT
Volume:152.96K
Turnover:3.20M
Market Cap:688.12M
PE:-16.19
High:21.29
Open:20.11
Low:19.88
Close:20.13
52wk High:29.28
52wk Low:5.55
Shares:32.58M
Float Shares:21.23M
Volume Ratio:0.86
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3045
EPS(LYR):-1.3236
ROE:-214.58%
ROA:-73.07%
PB:75.77
PE(LYR):-15.96

Loading ...

Nuvectis Pharma Inc Expected to Post a Loss of 26 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Maxim Group Keeps Their Buy Rating on Nuvectis Pharma (NVCT)

TIPRANKS
·
Jul 24

Nuvectis’ NXP100 Just Achieved the First Marketing Approval Ever for a Once-Daily Oral Factor B Inhibitor

TIPRANKS
·
Jul 24

Pantginis Reiterates Buy on Nuvectis, Citing Ciprocopan Approval and Pipeline Diversification; Price Target Maintained at $39

TIPRANKS
·
Jul 23

Nuvectis Pharma Says Paroxysmal Nocturnal Hemoglobinuria Drug Approved by Chinese Regulator

MT Newswires Live
·
Jul 23

Nuvectis Corrects Title of Ciprocopan China Marketing Approval Release

Reuters
·
Jul 23

Nuvectis Pharma receives marketing approval in China for ciprocopan

TIPRANKS
·
Jul 23

Nuvectis Says China Regulator Approves Ciprocopan for Treatment-naive PNH Patients

Reuters
·
Jul 23

Nuvectis Pharma - Ciprocopan (nxp100) Receives Marketing Approval in China for Treatment-naive Pnh Patients

THOMSON REUTERS
·
Jul 23

Nuvectis Pharma’s NXP900 Combo Trial Adds Fresh Momentum to NVCT in EGFR Lung Cancer

TIPRANKS
·
Jul 10

The Billion-Dollar Pill: With NXP100, Nuvectis Pharma Just Staked Its Claim in the New Biotech Gold Rush

TIPRANKS
·
Jul 09

Nuvectis Pharma is Maintained at Buy by Roth Capital

Dow Jones
·
Jul 06

Nuvectis Pharma price target raised to $33 from $20 at Roth Capital

TIPRANKS
·
Jul 06

Insiders Make Bold Move as Nuvectis Pharma Leadership Ramps Up Buying Spree

TIPRANKS
·
Jul 02

Nuvectis Pharma Chairman, CEO Ron Bentsur Buys USD 250,000 Common Shares

Reuters
·
Jul 02

Concentrix Reports Downbeat Q2 Earnings, Joins Nuvectis Pharma, Vishay Intertechnology And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Benzinga_recent_news
·
Jun 30

Nuvectis Pharma Tumbles on Deep-discounted $100 Mln Share Sale

Reuters
·
Jun 30

Top Premarket Decliners

MT Newswires Live
·
Jun 30

Nuvectis Pharma Prices 5 Million-share Offering at $20, Raising $100 Million

Reuters
·
Jun 30

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

TIPRANKS
·
Jun 30